

## Review Article

# A Review on Vitamin B12 and Iron Deficiency Anaemia Linked with Persistent Use of Gastric Acid Suppressants

Arumugavignesh M<sup>1\*</sup>, Jeya Ananthi J<sup>2</sup>, Soffia Mary J<sup>1</sup>, Jessica P<sup>1</sup>, Nandhini S R<sup>1</sup>

<sup>1</sup>Arulmigu Kalasalingam College of Pharmacy, Krishnankoil, Tamilnadu, India.

<sup>2</sup>Department of Pharmaceutics, Arulmigu Kalasalingam College of Pharmacy, Krishnankoil, Tamilnadu, India.

### ARTICLE INFO

#### Article history:

Received 04 Dec 2020

Received in revised form 15 Dec 2020

Accepted 17 Dec 2020

[doi.org/10.38111/ijapb.20200604004](https://doi.org/10.38111/ijapb.20200604004)

#### Keywords:

Anaemia, Acid suppressants,  
Hemoglobin, Vitamin-B12 deficiency,  
Iron deficiency

### ABSTRACT

Globally Anaemia is a public health hurdle influencing both developing and developed countries at all ages. World Health Organization (WHO) defines Anaemia as the hemoglobin (Hb) levels <12.0 g/dl in women and <13.0 g/dl in men. Etiology of Anaemia is often multi factorial. Among those, prolonged use of acid suppressants in hospitalized, ambulatory and non ambulatory patient setting is a notorious one. Acid suppressants are the therapeutic agents which prove to be effective in the treatment of common gastro intestinal disorders like peptic ulcer, Gastro Esophageal Reflux Disease etc. Acid suppressants can be classified into three pharmacological classes namely histamine-2 receptor antagonists, proton pump inhibitors and miscellaneous. These are often used for prolonged period of time in many a circumstances to inhibit the secretion of gastric acid. The gastric acid is necessary for the absorption of Vitamin-B 12 and Iron. This paves the way for the incidence of Iron and Vitamin-B12 deficiency Anaemia in some patients as an adverse effect. This review exemplifies the mechanism associated with this and also compares the results of various research works, case reports those are similar to this topic. It also sheds light towards the clinical management of different types of Anaemia induced by persistent use of acid suppressants.

## 1. Introduction

Anaemia is an intercontinental public health hurdle influencing both developing, developed and underdeveloped countries at all ages. World Health Organization (WHO) defines Anaemia as the hemoglobin (Hb) levels <12.0 g/dl in women and <13.0 g/dl in men.<sup>[1]</sup> Most of the Anaemia is related to the gastro intestinal system by nutritional deficiency, mal absorption, or chronic hemorrhage.<sup>[2]</sup> Anaemia contributes to 8.8% of the total malady from all conditions in the year 2010. Children less than five years and women are more vulnerable to this. Although iron-deficiency Anaemia is the most common etiology globally, other leading causative factors of Anaemia vary significantly by geography, age, and gender.<sup>[3]</sup> Besides that Anaemia is often under diagnosed in both clinical and outpatient settings. If left untreated, Anaemia put forth various health risks

like sever fatigue, tissue hypoxia, pregnancy complications, heart problems and even sometimes fatal.

Acid suppressants are inevitable agents used in the treatment of gastro intestinal ailments like peptic ulcer, drug induced ulcers and Gastro Esophageal Reflux Disease (GERD).<sup>[4]</sup> Acid suppressants are pharmacologically classified into two broad categories namely histamine-2 receptor antagonists (H2RAs) and proton pump inhibitors (PPIs). Other miscellaneous classes of drugs are also used in some clinical conditions. Nevertheless, their prolonged use is attributed to various hematological adverse effects. Among those decreased dietary iron and vitamin B-12 absorption is a noteworthy one.<sup>[5]</sup> This review discusses the mechanism associated with acid suppressants induced Vitamin-B<sub>12</sub> deficiency, Iron deficiency Anaemia and also compares the results of various research works, case reports those are similar to our study topic.

\* Corresponding author. Tel.: +918072046740.  
E-mail address: [m.arumugavignesh20@gmail.com](mailto:m.arumugavignesh20@gmail.com)



### Iron Deficiency Anaemia

Iron deficiency Anaemia (IDA) is the most prevalent form of Anaemia in this earth.<sup>[6]</sup> Under the morphological classification of WHO, it comes under microcytic hypochromic Anaemia. Menstruating women, pregnant women and children below five years of age who have diet low in iron are at high risk of getting IDA.<sup>[7]</sup> Patients with gastro intestinal disorders like peptic ulcer, inflammatory bowel disease are also at the same risk. In the human body, iron is ubiquitous in all cells. It has many significant functions such as transporting oxygen to the tissues from the lungs in the form of hemoglobin (Hb). It also promotes oxygen utility and stockpile in the muscles as myoglobin and act as a carrier medium for electrons within the cells in the form of cytochromes. It is also an integral component of enzyme reactions in variety of tissues. Hence it is understood that deficiency of iron can interrupt all these vital functions and results in significant rate of morbidity and mortality.<sup>[8]</sup> Iron is available in ferric ( $\text{Fe}^{3+}$ ) the most stable form in most of the food substances.<sup>[9]</sup> Indeed, it is better absorbed in ferrous ( $\text{Fe}^{2+}$ ) form. Stomach hydrochloric acid plays a significant part in the conversion of ferric form to ferrous form.<sup>[10]</sup> Duodenum and proximal jejunum are the principal sites of absorption for dietary iron.<sup>[11]</sup>

The Recommended Daily Allowance (RDA) of Iron is 13.7–15.1 mg/D in children aged 2–11 years, 16.3 mg/D in children and teens aged 12–19 years, and 19.3–20.5 mg/D in men and 17.0–18.9 mg/D in women older than 19. The median dietary iron intake in pregnant women is 14.7 mg/day.<sup>[12]</sup> Red meat, pork, poultry, seafood, beans, dark green leafy vegetables such as spinach, dried fruit such as raisins and apricots, Iron-fortified cereals, breads and pastas, Peas are the food products that are found to be rich sources of iron.<sup>[13]</sup>

The clinical investigation criteria for iron deficiency Anaemia are low hemoglobin (<7.7 mmol/l in men and 7.4 mmol/l in women), a low serum iron (<7.1  $\mu\text{g/l}$ ), a low serum ferritin (storage form of iron) (<30 ng/l), a low transferrin saturation (<15%), and a high total iron-binding capacity (>13.1  $\mu\text{mol/l}$ ).<sup>[14]</sup>

IDA can be treated with oral and parenteral therapy. In asymptomatic and mildly symptomatic patients with IDA, oral iron replacement is the common evidence based treatment. Various other oral iron salts like ferrous sulfate, ferrous gluconate, and ferrous fumarate are now available.<sup>[15]</sup> Ferrous sulfate is used widely among these three products. Parenteral iron therapy is confined to patients who have mal absorptive diseases. High molecular weight dextran, low molecular weight dextran, Iron sucrose, Sodium ferric gluconate complex are the available forms of parenteral iron supplement for the treatment.<sup>[16]</sup>

### Vitamin-B<sub>12</sub> deficiency Anaemia


Vitamin-B<sub>12</sub> deficiency Anaemia is the second most prevalent forms of Anaemia in the recent decade. It is also known as pernicious Anaemia.<sup>[17]</sup> Cobalamin is another name for Vitamin-B<sub>12</sub>. Morphologically, it comes under megaloblastic Anaemia. Strict vegans, babies of lactating mothers who have vitamin-B<sub>12</sub> deficiency, geriatrics, chronic alcoholics are at high risk of developing vitamin B<sub>12</sub> deficiency Anaemia.<sup>[18]</sup> Patients who are having atrophic gastritis, people who are lacking intrinsic factors (IF) are also at high risk.<sup>[19]</sup> Vitamin-B<sub>12</sub> as a supplement is essential for the production of red blood cells and DNA (De oxy ribo Nucleic Acid), the genetic material in humans. It also especially plays a vital role in the normal functioning of neurons.<sup>[20]</sup> Deficiency of vitamin-B<sub>12</sub> affects all these vital functions. In food products, vitamin-B<sub>12</sub> is present as bounded to protein. Stomach's hydrochloric acid plays a significant role in the separation of vitamin-B<sub>12</sub> from the bound protein.<sup>[21]</sup> Then vitamin-B<sub>12</sub> is conjugated with intrinsic factor (IF) which is secreted by the parietal cells of stomach.

Consequently it gets absorbed primarily in distal ileum and then to the systemic circulation for the physiological need.<sup>[22]</sup>

Recommended daily intake of Vitamin-B<sub>12</sub> is 0.9  $\mu\text{g}$  in children below nine years, 2.4  $\mu\text{g}$  in children above nine years and adults, 2.6  $\mu\text{g}$  in pregnant women and 2.8  $\mu\text{g}$  in breast feeding mothers.<sup>[23]</sup> Clams and beef liver are the richest sources of vitamin B<sub>12</sub>. Fish, eggs, poultry, meat, milk, and other dairy products also contain vitamin-B<sub>12</sub> in significant quantity.

The conclusive test of serum cobalamin levels which if less than 148 pmol/L is highly sensitive for the confirmation of Vitamin-B<sub>12</sub> deficiency Anaemia.<sup>[24]</sup> Till today there is no 'gold standard' criteria available for the detection of vitamin-B<sub>12</sub> deficiency and as a result, the diagnosis requires both clinical manifestations of the patient and the results of investigations. The anti-IF antibody test is a specific investigation for the diagnosis of pernicious Anaemia caused by the insufficient secretion of intrinsic factor from gastric parietal cells.<sup>[25]</sup>

Oral, parenteral and nasal formulations are available for the management of Vitamin-B<sub>12</sub> deficiency Anaemia.<sup>[26]</sup> Patients with no neurological manifestations are treated usually with the regimen of hydroxocobalamin 1 mg on alternate days for two weeks. It is then followed by three-monthly injections of hydroxocobalamin 1 mg.<sup>[27]</sup> Vitamin-B<sub>12</sub> is ready for use as a nasal spray for patients in remission succeeding intramuscular administration who have no neurological manifestations.<sup>[28]</sup> The nasal spray 500  $\mu\text{g/Week}$  is administered once weekly.



**Figure 1.** Portraits the mechanism of PPIs induced Iron and Vitamin-B<sub>12</sub> deficiency Anaemia

### Mechanism behind acid suppressants' induced Iron deficiency Anaemia

Acid suppressants are pharmacologically categorized into two types; H<sub>2</sub> blockers and proton pump inhibitors. Histamine-2 blockers are now are in hand both as over the counter drugs and as prescription drugs. Cimetidine was the first introduced H<sub>2</sub> blocker.<sup>[29]</sup> Ranitidine, Nizatidine and Famotidine are the familiar ones. These drugs are antagonists of parietal cell H<sub>2</sub> receptors, declining cAMP (cyclic Adenosine Mono Phosphate) and resultant H<sup>+</sup>/K<sup>+</sup> pump activity.<sup>[30]</sup> H<sub>2</sub> receptor antagonists block basal levels of gastric acid secretion and may block meal-stimulated secretion (which is gastrin mediated) to some extent. As a result of stop up of gastric acid secretion and usage of H<sub>2</sub> blockers for prolonged period, dietary iron cannot be absorbed properly and finally leads to Iron deficiency Anaemia.<sup>[31]</sup> This is because of necessity of low pH of gastric acid in the proximal duodenum to allow ferric reductase enzyme and duodenal cytochrome B (Dcytb), on the brush border membrane of the enterocytes to

transmogrify the insoluble ferric (Fe<sup>3+</sup>) to absorbable ferrous (Fe<sup>2+</sup>) ions.<sup>[32]</sup> The gastric acid is also responsible plasma iron homeostasis. Similarly Proton pump inhibitors (PPIs) like omeprazole, pantoprazole etc impedes the secretion of gastric acid by binding covalently with *H<sup>+</sup>/K<sup>+</sup>-ATPase* enzyme which eases the way for hydrogen and potassium exchange through parietal cells, which results in the export of potassium and generation of HCl (gastric acid).<sup>[33]</sup> This extended inhibition of gastric acid secretion finally leads dwindles iron absorption and results in Iron deficiency Anaemia.<sup>[34]</sup>

### ***Mechanism behind acid suppressants' induced Vitamin-B12 deficiency Anaemia***

Vitamin-B<sub>12</sub> (cobalamin) in food products is almost found to be bound with proteins. After ingestion, the low stomach pH created by gastric acid liberates cobalamin from other dietary protein. The free cobalamin then aggregates with the gastric R binder (transcobalamin), a glycoprotein in saliva, and the aggregate travels to the duodenum and jejunum.<sup>[35]</sup> The pancreatic peptidases assimilate the aggregate and release cobalamin. Then, it ties up with gastric intrinsic factor (IF), a glycoprotein produced by gastric parietal cells, secretions of which is equivalent to that of gastric acid secretion.<sup>[36]</sup> Cobalamin complexed with IF then gets absorbed in ileum of small intestine. Hence, in states of prolonged use of acid suppressants like H<sub>2</sub> blockers and Proton pump inhibitors both IF secretion and gastric acid secretion is reduced.<sup>[37]</sup> Thus, this mechanism greatly restrains the absorption of Vitamin-B<sub>12</sub> which eventually leads to the incurrence of Vitamin-B<sub>12</sub> deficiency Anaemia.<sup>[38]</sup>

## **2. Discussion**

Here with, from our review we discuss and compare the results of various case reports and research articles to espouse the confirmation of prevalence of acid suppressants' induced Iron and Vitamin-B<sub>12</sub> deficiency Anaemia. A retrospective cohort study conducted by Erin Sarzynski *et al* strongly proves the remarkable decline in hematologic indices from baseline among adult patients who were chronic users of proton pump inhibitors in an outpatients setting. They found a notable decrease in hematologic indices with the inclusion of hemoglobin (P=0.03), hematocrit (P=0.02), and mean corpuscular volume (P=0.05).<sup>[39]</sup> A community based case-control study conducted by Jameson R *et al* robustly correlates the relationship between prolonged acid suppressants intake and iron deficiency Anaemia. They found that among 77,046 Iron deficiency anemic patients, 2343 (3.0%) were provided with the earlier supply of PPIs and 1063 (1.4%) were received a prior supply of H<sub>2</sub>RAs for > two years.<sup>[40]</sup> A case-control study done using CPRD Gold by Tran-Duy A *et al* confirms the positive association between chronic PPI use in terms and conditions of both duration and frequency of pharmacotherapy and soared up risk of iron deficiency Anaemia. The total cases were found to be 26,806 in this study. The quantitative data of full users of proton pump inhibitors, limited users of proton pump inhibitors or non users of proton pump inhibitors in cases and controls are significantly different (p-value< 0.001).<sup>[41]</sup> A case report of 52 year old man reviewed by Ryosuke Imai *et al* reports the development of Iron deficiency Anaemia in that patient who had been taking omeprazole for the past 25 years.<sup>[42]</sup>

A case-control study in a University-based geriatric primary care setting conducted by Valuck R J *et al* divulged the increased risk of vitamin-B<sub>12</sub> deficiency resulted due to use of H<sub>2</sub>RA/PPI s (OR 4.45; 95% CI 1.47-13.34).<sup>[43]</sup> A roosted case-control study within the Kaiser Permanente

Northern California (KPNC) integrated healthcare system conducted by Lam J R *et al* confirms the relationship between previous and current gastric acid suppressants use with the existence of vitamin B<sub>12</sub> deficiency.<sup>[44]</sup> A case report of 78-year-old non vegetarian white woman with symptomatic gastro esophageal reflux reviewed by Ruscin J M *et al* confirms the development of vitamin B<sub>12</sub> deficiency associated with long-term use (~4½ years) of histamine<sub>2</sub> (H<sub>2</sub>)-receptor antagonists and a proton-pump inhibitor (PPI).<sup>[45]</sup> A cross-sectional sample analysis of 659 adult patients done by Dharmarajan T S *et al* reports the downturn of Vitamin-B<sub>12</sub> level during extensive PPIs use in older adults, but not with extensive H<sub>2</sub> blocker use.<sup>[46]</sup>

## **3. Conclusion**

Iron and Vitamin-B12 deficiency occurs more habitually in patients who are taking acid suppressants for a prolonged period of time. Patients should not be prescribed unnecessarily with acid suppressants without any proper clinical indication. Clinicians should be prudently vigilant while prescribing these drugs and should scrupulously use the lowest possible effective doses as per the individual's requirement. Prescribing doses of acid suppressant drugs should be optimized rationally as per ethical and professional consensus. Regular monitoring of Iron and Vitamin-B12 status in patients who are taking acid suppressants for prolonged period is necessitated. Iron and Vitamin-B12 supplements may not be helpful to overcome this while concomitantly using acid suppressants. However, with drawl of acid suppressants can provide beneficial outcomes. In the near future further studies in these aspects would enhance reduction in the mortality and morbidity of Anaemia.

## **Acknowledgements**

We express our wholehearted thanks to our principal and all other faculty members for guiding and supporting us to do this review.

## **Conflict of Interest**

The author(s) confirm that this article content has no conflict of interest.

## **References**

1. Cappellini MD, Motta I. Anaemia in clinical practice—definition and classification: does hemoglobin change with aging?. In *Seminars in hematology* 2015 Oct 1 (Vol. 52, No. 4, pp. 261-269). WB Saunders.
2. Chulilla JA, Colás MS, Martín MG. Classification of Anaemia for gastroenterologists. *World Journal of Gastroenterology: WJG.* 2009 Oct 7;15(37):4627.
3. Kassebaum NJ, Jasrasaria R, Naghavi M, Wulf SK, Johns N, Lozano R, Regan M, Weatherall D, Chou DP, Eisele TP, Flaxman SR. A systematic analysis of global Anaemia burden from 1990 to 2010. *Blood.* 2014 Jan 30;123(5):615-24.
4. Kim TJ, Kim ER, Hong SN, Kim YH, Lee YC, Kim HS, Kim K, Chang DK. Effectiveness of acid suppressants and other mucoprotective agents in reducing the risk of occult gastrointestinal bleeding in nonsteroidal anti-inflammatory drug users. *Scientific reports.* 2019 Aug 12;9(1):1-8.
5. Aymard JP, Aymard B, Netter P, Bannwarth B, Trechot P, Streiff F. Haematological adverse effects of histamine H<sub>2</sub>-receptor

- antagonists. *Medical toxicology and adverse drug experience.* 1988 Dec 1;3(6):430-48.
6. Camaschella C. Iron-deficiency Anaemia. *New England journal of medicine.* 2015 May 7;372(19):1832-43.
  7. Killip S, Bennett JM, Chambers MD. Iron deficiency Anaemia. *American family physician.* 2007 Mar 1;75(5):671-8.
  8. Kohgo Y, Ikuta K, Ohtake T, Torimoto Y, Kato J. Body iron metabolism and pathophysiology of iron overload. *International journal of hematology.* 2008 Jul 1;88(1):7-15.
  9. Lee K, YDESDALE FC. Quantitative determination of the elemental, ferrous, ferric, soluble, and complexed iron in foods. *Journal of Food Science.* 1979 Mar;44(2):549-54.
  10. Schade SG, Cohen RJ, Conrad ME. Effect of hydrochloric acid on iron absorption. *New England Journal of Medicine.* 1968 Sep 26;279(13):672-4.
  11. West AR, Oates PS. Mechanisms of heme iron absorption: current questions and controversies. *World journal of gastroenterology: WJG.* 2008 Jul 14;14(26):4101.
  12. US National Institutes of Health. Office of Dietary Supplements. Iron fact sheet for health professionals [cited 2018 Aug 13].
  13. Bothwell TH, Baynes RD, MacFarlane BJ, MacPhail AP. Nutritional iron requirements and food iron absorption. *Journal of internal medicine.* 1989 Nov;226(5):357-65.
  14. Johnson-Wimbley TD, Graham DY. Diagnosis and management of iron deficiency Anaemia in the 21st century. *Therapeutic advances in Gastroenterology.* 2011 May;4(3):177-84.
  15. Zhu A, Kaneshiro M, Kaunitz JD. Evaluation and treatment of iron deficiency Anaemia: a gastroenterological perspective. *Digestive diseases and sciences.* 2010 Mar 1;55(3):548-59.
  16. Dillon R, Momoh I, Francis Y, Cameron L, Harrison CN, Radia D. Comparative efficacy of three forms of parenteral iron. *Journal of blood transfusion.* 2012;2012.
  17. Stabler SP. Vitamin B12 deficiency. *New England Journal of Medicine.* 2013 Jan 10;368(2):149-60.
  18. Pawlak R, Lester SE, Babatunde T. The prevalence of cobalamin deficiency among vegetarians assessed by serum vitamin B12: a review of literature. *European journal of clinical nutrition.* 2014 May;68(5):541-8.
  19. Supiano MA. Atrophic Gastritis and Vitamin B12 Deficiency.
  20. Fenech M. The role of folic acid and vitamin B12 in genomic stability of human cells. *Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis.* 2001 Apr 18;475(1-2):57-67.
  21. Shipton MJ, Thachil J. Vitamin B12 deficiency—A 21st century perspective. *Clinical medicine.* 2015 Apr;15(2):145.
  22. Booth CC, Mollin DL. The site of absorption of vitamin B12 in man. *Lancet.* 1959;1:18-21.
  23. Morris MC, Evans DA, Bienias JL, Tangney CC, Hebert LE, Scherr PA, Schneider JA. Dietary folate and vitamin B12 intake and cognitive decline among community-dwelling older persons. *Archives of neurology.* 2005 Apr 1;62(4):641-5.
  24. Hvas AM, Nexø E. Diagnosis and treatment of vitamin B12 deficiency—an update. *Haematologica.* 2006 Jan 1;91(11):1506-12.
  25. Festen HP. Intrinsic factor secretion and cobalamin absorption: physiology and pathophysiology in the gastrointestinal tract. *Scandinavian Journal of Gastroenterology.* 1991 Jan 1;26(sup188):1-7.
  26. Thakkar K, Billa G. Treatment of vitamin B12 deficiency—Methylcobalamine? Cyanocobalamine? Hydroxocobalamine?—clearing the confusion. *European journal of clinical nutrition.* 2015 Jan;69(1):1-2.
  27. Vidal - Alaball J, Butler C, Cannings - John R, Goringe A, Hood K, McCaddon A, McDowell I, Papaioannou A. Oral vitamin B12 versus intramuscular vitamin B12 for vitamin B12 deficiency. *Cochrane Database of Systematic Reviews.* 2005(3).
  28. Rozgonyi NR, Fang C, Kuczmarski MF, Bob H. Vitamin B12 deficiency is linked with long-term use of proton pump inhibitors in institutionalized older adults: could a cyanocobalamin nasal spray be beneficial?. *Journal of Nutrition for the Elderly.* 2010 Feb 24;29(1):87-99.
  29. Nugent CC, Terrell JM. H2 Blockers. InStatPearls [Internet] 2019 May 7. StatPearls Publishing.
  30. Feldman M, Burton ME. Histamine2-receptor antagonists: standard therapy for acid-peptic diseases. *New England Journal of Medicine.* 1990 Dec 13;323(24):1672-80.
  31. Alleyne M, Horne MK, Miller JL. Individualized treatment for iron-deficiency Anaemia in adults. *The American journal of medicine.* 2008 Nov 1;121(11):943-8.
  32. Ganasen M, Togashi H, Takeda H, Asakura H, Tosha T, Yamashita K, Hirata K, Nariai Y, Urano T, Yuan X, Hamza I. Structural basis for promotion of duodenal iron absorption by enteric ferric reductase with ascorbate. *Communications biology.* 2018 Aug 17;1(1):1-2.
  33. Mullin JM, Gabello M, Murray LJ, Farrell CP, Bellows J, Wolow KR, Kearney KR, Rudolph D, Thornton JJ. Proton pump inhibitors: actions and reactions. *Drug discovery today.* 2009 Jul 1;14(13-14):647-60.
  34. McColl KE. Effect of proton pump inhibitors on vitamins and iron. *American Journal of Gastroenterology.* 2009 Mar 1;104:S5-9.
  35. Seetharam B, Alpers DH. Absorption and transport of cobalamin (vitamin B12). *Annual review of nutrition.* 1982 Jul;2(1):343-69.
  36. Stabler SP. Vitamin B12 deficiency. *New England Journal of Medicine.* 2013 Jan 10;368(2):149-60.
  37. Booth CC, Mollin DL. The site of absorption of vitamin B12 in man. *Lancet.* 1959;1:18-21.
  38. Kinoshita Y, Ishimura N, Ishihara S. Advantages and disadvantages of long-term proton pump inhibitor use. *Journal of neurogastroenterology and motility.* 2018 Apr;24(2):182.
  39. Force RW, Meeker AD, Cady PS, Culbertson VL, Force WS, Kelley CM. Increased vitamin B12 requirement associated with chronic acid suppression therapy. *Annals of Pharmacotherapy.* 2003 Apr;37(4):490-3.
  40. Sarzynski E, Puttarajappa C, Xie Y, Grover M, Laird-Fick H. Association between proton pump inhibitor use and Anaemia: a retrospective cohort study. *Digestive diseases and sciences.* 2011 Aug 1;56(8):2349-53.
  41. Lam JR, Schneider JL, Quesenberry CP, Corley DA. Proton pump inhibitor and histamine-2 receptor antagonist use and iron deficiency. *Gastroenterology.* 2017 Mar 1;152(4):821-9.
  42. Tran - Duy A, Connell NJ, Vanmolokot FH, Sovereign PC, de Wit NJ, Stehouwer CD, Hoes AW, de Vries F, de Boer A. Use of proton pump inhibitors and risk of iron deficiency: a population - based case - control study. *Journal of internal medicine.* 2019 Feb;285(2):205-14.

43. Imai R, Higuchi T, Morimoto M, Koyamada R, Okada S. Iron deficiency Anaemia due to the long-term use of a proton pump inhibitor. *Internal Medicine*. 2018 Mar 15;57(6):899-901.
44. Valuck RJ, Ruscin JM. A case-control study on adverse effects: H2 blocker or proton pump inhibitor use and risk of vitamin B12 deficiency in older adults. *Journal of clinical epidemiology*. 2004 Apr 1;57(4):422-8.
45. Lam JR, Schneider JL, Zhao W, Corley DA. Proton pump inhibitor and histamine 2 receptor antagonist use and vitamin B12 deficiency. *Jama*. 2013 Dec 11;310(22):2435-42.
46. Ruscin JM, Lee Page R, Valuck RJ. Vitamin B12 deficiency associated with histamine2-receptor antagonists and a proton-pump inhibitor. *Annals of Pharmacotherapy*. 2002 May;36(5):812-6.
47. Dharmarajan TS, Kanagala MR, Murakonda P, Lebelt AS, Norkus EP. Do acid-lowering agents affect vitamin B12 status in older adults?. *Journal of the American Medical Directors Association*. 2008 Mar 1;9(3):162-7.